These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8851208)

  • 1. The influence of CD4+ T cells, HIV disease stage and zidovudine on HIV isolation in Bahia, Brazil.
    Brites C; Pedroso C; Silva N; Johnson WD; Badaró R
    Rev Soc Bras Med Trop; 1996; 29(1):5-9. PubMed ID: 8851208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression.
    Carrière D; Vendrell J; Berthier A; Atoui N; Salhi SL; Reynes J; Gros P; Fontaine C; Jansen A; Huguet M; Ait-Cheik L; Pau B
    J Infect Dis; 1996 Mar; 173(3):565-73. PubMed ID: 8627018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
    Fischl MA; Resnick L; Coombs R; Kremer AB; Pottage JC; Fass RJ; Fife KH; Powderly WG; Collier AC; Aspinall RL
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):139-47. PubMed ID: 7905523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 status and P24 antigenemia. Are they useful predictors of survival in HIV-infected children receiving antiretroviral therapy?
    Butler KM; Husson RN; Lewis LL; Mueller BU; Venzon D; Pizzo PA
    Am J Dis Child; 1992 Aug; 146(8):932-6. PubMed ID: 1353299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
    Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P
    AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
    Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.
    Boyer PJ; Dillon M; Navaie M; Deveikis A; Keller M; O'Rourke S; Bryson YJ
    JAMA; 1994 Jun 22-29; 271(24):1925-30. PubMed ID: 7911164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    Mueller BU; Sei S; Anderson B; Luzuriaga K; Farley M; Venzon DJ; Tudor-Williams G; Schwartzentruber DJ; Fox C; Sullivan JL; Pizzo PA
    J Pediatr; 1996 Sep; 129(3):410-8. PubMed ID: 8804331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of cells positive for HIV-1 p24 antigen assessed by flow cytometry.
    Holzer TJ; Heynen CA; Novak RM; Pitrak DL; Dawson GJ
    AIDS; 1993 Nov; 7 Suppl 2():S3-5. PubMed ID: 7909224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection.
    Ohlsson-Wilhelm BM; Cory JM; Kessler HA; Eyster ME; Rapp F; Landay A
    J Infect Dis; 1990 Nov; 162(5):1018-24. PubMed ID: 1977803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression.
    Schechter M; Harrison LH; Halsey NA; Trade G; Santino M; Moulton LH; Quinn TC
    JAMA; 1994 Feb; 271(5):353-7. PubMed ID: 7904317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.